Publications

European radiology

Watchful waiting for ductal carcinoma in situ: are we ready to step back?

01-08-2025

Cellular oncology (Dordrecht, Netherlands)

Absence of lipopolysaccharide (LPS) expression in breast cancer cells.

01-08-2025

British journal of cancer

Development of radiomics-based models on mammograms with mass lesions to predict prognostically relevant characteristics of invasive breast cancer in a screening cohort.

01-06-2025

Cancer epidemiology

Notification of locoregional breast cancer recurrence based on pathology reports: A nationwide validation study with the Netherlands Cancer Registry.

01-06-2025

EBioMedicine

Deep learning for predicting invasive recurrence of ductal carcinoma in situ: leveraging histopathology images and clinical features.

01-06-2025

NPJ breast cancer

Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study.

29-05-2025

European radiology

Correction: Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer.

01-04-2025

European journal of cancer (Oxford, England : 1990)

Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial.

25-02-2025

NPJ breast cancer

A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer.

13-02-2025

Clinical oncology (Royal College of Radiologists (Great Britain))

Deintensification of Radiotherapy Use in Treatment of Ductal Carcinoma In Situ in the Netherlands-A Nationwide Overview From 2008 Until 2022.

01-02-2025

NPJ precision oncology

A morphometric signature to identify ductal carcinoma in situ with a low risk of progression.

28-01-2025

Cancer discovery

Conquering Overtreatment of DCIS: Lessons from PRECISION.

13-01-2025

Nature

The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy.

01-01-2025

European journal of cancer (Oxford, England : 1990)

Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study.

01-12-2024

European radiology

Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer.

01-12-2024

Future oncology (London, England)

An early economic evaluation of active surveillance for low-risk ductal carcinoma in situ.

01-12-2024

Breast (Edinburgh, Scotland)

DCIS knowledge of women choosing between active surveillance and surgery for low-risk DCIS.

01-10-2024

British journal of cancer

Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands: time trends and the association with tumour grade.

01-09-2024

Breast cancer research : BCR

Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance.

27-08-2024

iScience

Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.

16-08-2024

The Journal of pathology

Ductal carcinoma in situ develops within clonal fields of mutant cells in morphologically normal ducts.

01-07-2024

Lancet (London, England)

Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.

22-06-2024

The Lancet. Oncology

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.

01-05-2024

Cancer imaging : the official publication of the International Cancer Imaging Society

Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trials.

05-04-2024

ESMO open

Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer.

01-03-2024

Breast cancer research and treatment

The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch population.

01-02-2024

The Journal of pathology

Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas.

01-02-2024

BMJ (Clinical research ed.)

Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ.

24-01-2024

Molecular oncology

Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1-NDRG1 deregulation.

01-01-2024

Research square

Artificial intelligence-based morphometric signature to identify ductal carcinoma in situ with low risk of progression to invasive breast cancer.

13-12-2023

Insights into imaging

Clinicopathological and prognostic value of calcification morphology descriptors in ductal carcinoma in situ of the breast: a systematic review and meta-analysis.

05-12-2023

Cancer epidemiology

Impact of the COVID-19 pandemic on breast cancer incidence and tumor stage in the Netherlands and Norway: A population-based study.

01-12-2023

Breast cancer research : BCR

PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning.

13-11-2023

BMJ (Clinical research ed.)

Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.

30-10-2023

Cell reports. Medicine

Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2⁺ breast cancer.

17-10-2023

European journal of cancer (Oxford, England : 1990)

Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.

01-10-2023

NPJ breast cancer

High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial.

09-09-2023

British journal of cancer

Correction To: Tumour-educated platelets for breast cancer detection: biological and technical insights.

01-09-2023

Cell

Archival single-cell genomics reveals persistent subclones during DCIS progression.

31-08-2023

Breast cancer research : BCR

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.

19-06-2023

Scientific reports

Microcalcification crystallography as a potential marker of DCIS recurrence.

08-06-2023

Cancer cell

A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.

08-05-2023

Nature communications

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.

07-04-2023

British journal of cancer

Tumour-educated platelets for breast cancer detection: biological and technical insights.

01-04-2023

Nature reviews. Cancer

Author Correction: Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

01-02-2023

Breast cancer research and treatment

Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study.

01-01-2023

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer.

01-12-2022

Nature reviews. Cancer

Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

01-12-2022

Journal of geriatric oncology

Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study.

01-11-2022

Clinical cancer research : an official journal of the American Association for Cancer Research

Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers.

14-10-2022